Pharmasol and PharmaLex Complete Strategic Merger

Specialist software provider, pharmasol, announced in a Feb 2, 2022 press release, that it has completed the strategic merger with PharmaLex—a provider of specialized services for the pharma, biotech, and medtech sectors.

Through the merger, PharmaLex will gain pharmasol’s SUSAR (Suspected Unexpected Serious Adverse Reactions) distribution platform. Additionally, pharmasol will provide key pharmacovigilance and end-to-end business support expertise to the newly expanded PharmaLex group.

“This strategic partnership with PharmaLex is a key milestone in our mission to create a dominant market position and enhance our total solution portfolio offering to our clients,” said pharmasol CEO Torsten Adam, in the press release. “This landmark alliance empowers both organizations to offer greater depth and breadth of service in the fast-growing and highly competitive area of pharmacovigilance—from best-in-class IT solutions, hosting and business process automation to strategic consultancy services.”

“We are delighted to have completed this strategic merger with pharmasol, and to be enhancing our solution set with pharmasol’s proven, specialist solutions that support companies to cost-effectively and efficiently meet their regulatory and operational responsibilities while increasing compliance,” added PharmaLex CEO Thomas Dobmeyer, in the press release. “With this consolidation of expertise from two industry leaders, we are excited to be further expanding our capabilities, and providing customers with access to pharmasol’s unparalleled technical expertise, highly talented team, and scalable, next-generation technology that will be instrumental in helping the industry to meet the complex data strategy and governance challenges, now and in the future.”

Source: pharmasol